15 Days Price Change
Closing In
WEBSITE Inc. Year: 2001 Industry: Chemicals Listed Page
Buy unlisted shares early and participate in the growth before public listing.
Face Value 10 per share
Price 210 to 221 per share
P/E (x) 13.6
Sales( Cr.) 848
PAT( Cr.) 67
EPS 16.3
Draft Prospectus --
Exchange BSE-NSE
Company Promoters
Pre Issue Share Holding 100%
Post Issue Share Holding 46.44%
Listing Price: 211
Listing Gain: -4.74%
Current Price: 436.2
Gain On Issue: 436.2 | 0%
GMP: --
GMP %: -- %
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 67 | 14,807 |
| Retail (Max) | 13 | 871 | 192,491 |
| S-HNI (Min) | 14 | 938 | 207,298 |
| S-HNI (Max) | 67 | 4489 | 992,069 |
| B-HNI (Min) | 68 | 4556 | 1,006,876 |
1. Investment in Material Subsidiary, viz. BDJ Oxides (i) repayment or pre-payment, in full or in part, of all or certain borrowings availed by its Material Subsidiary (ii) funding capital expenditure requirements for setting up of a research and development center situated in Naidupeta, Andhra Pradesh (R& amp amp amp amp amp amp amp amp D Centre) (iii) funding its long-term working capital requirements. 2. Funding long-term working capital requirements of the Company. 3. General corporate purposes.
| Category | Nos | Bid | Bid (x) |
|---|---|---|---|
| QIB | 5683032 | 183732425 | 32.3x |
| NII | 1704909 | 81699239 | 47.9x |
| Retail | 3978122 | 71725540 | 18x |
| EMP | 0 | 0 | 0x |
| Total | 11366063 | 324160117 | 28.5x |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 250 | 339 | 399 | 435 | 613 | 785 | 668 | 848 | |
| Other Income | 1 | 3 | 8 | 7 | 10 | 11 | 8 | 13 | |
| Total Income | 251 | 343 | 408 | 442 | 623 | 796 | 676 | 861 | |
| Total Expenditure | 229 | 296 | 380 | 393 | 556 | 710 | 623 | 765 | |
| Operating Profit | 22 | 47 | 27 | 49 | 67 | 85 | 53 | 97 | |
| Interest | 6 | 6 | 6 | 5 | 7 | 5 | 4 | 1 | |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 3 | 5 | 5 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | |
| Profit Before Tax | 14 | 38 | 19 | 41 | 57 | 77 | 43 | 90 | |
| Provision for Tax | 5 | 13 | 5 | 12 | 14 | 20 | 11 | 23 | |
| Profit After Tax | 9 | 25 | 14 | 29 | 43 | 57 | 32 | 67 | |
| Adjustments | 0 | -2 | -1 | -5 | -3 | -2 | -1 | -3 | |
| Profit After Adjustments | 9 | 23 | 13 | 23 | 40 | 55 | 31 | 64 | |
| Adjusted Earnings Per Share | 2.9 | 7.3 | 4.1 | 7.4 | 12.6 | 17.3 | 7.9 | 16.3 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 31 | 54 | 85 | 108 | 153 | 208 | 398 | 465 |
| Minority's Interest | 0 | 2 | 5 | 11 | 4 | 6 | 7 | 10 |
| Borrowings | 14 | 8 | 6 | 5 | 6 | 7 | 4 | 0 |
| Other Non-Current Liabilities | 1 | 6 | 0 | 0 | 0 | 1 | -0 | 1 |
| Total Current Liabilities | 56 | 56 | 53 | 85 | 102 | 77 | 39 | 22 |
| Total Liabilities | 102 | 126 | 149 | 210 | 264 | 298 | 448 | 498 |
| Fixed Assets | 14 | 14 | 21 | 23 | 22 | 35 | 42 | 39 |
| Other Non-Current Assets | 1 | 2 | 10 | 11 | 18 | 6 | 13 | 15 |
| Total Current Assets | 87 | 110 | 119 | 176 | 224 | 256 | 394 | 444 |
| Total Assets | 102 | 126 | 149 | 210 | 264 | 298 | 448 | 498 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 0 | 1 | 1 | 5 | 6 | 4 | 47 |
| Cash Flow from Operating Activities | -14 | 19 | 41 | -7 | 7 | 31 | 76 | -11 |
| Cash Flow from Investing Activities | -6 | -2 | -11 | -6 | -5 | -5 | -140 | 25 |
| Cash Flow from Financing Activities | 18 | -16 | -30 | 17 | -0 | -29 | 107 | -29 |
| Net Cash Inflow / Outflow | -1 | 1 | -0 | 4 | 1 | -2 | 43 | -15 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 5 | 6 | 4 | 47 | 31 |
| # | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.91 | 7.27 | 4.08 | 7.39 | 12.61 | 17.32 | 7.87 | 16.34 |
| CEPS(Rs) | 3.43 | 8.58 | 4.99 | 9.82 | 14.44 | 18.99 | 9.35 | 18.41 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Book NAV/Share(Rs) | 9.71 | 16.98 | 26.78 | 34.2 | 48.11 | 65.47 | 101.67 | 118.6 |
| Core EBITDA Margin(%) | 8.31 | 12.74 | 4.81 | 9.65 | 9.25 | 9.45 | 6.73 | 9.8 |
| EBIT Margin(%) | 8.04 | 13.13 | 6.4 | 10.69 | 10.49 | 10.46 | 7.06 | 10.75 |
| Pre Tax Margin(%) | 5.79 | 11.32 | 4.79 | 9.46 | 9.37 | 9.78 | 6.46 | 10.6 |
| PAT Margin (%) | 3.67 | 7.43 | 3.49 | 6.62 | 7.04 | 7.24 | 4.81 | 7.87 |
| Cash Profit Margin (%) | 4.35 | 8.02 | 3.96 | 7.15 | 7.47 | 7.68 | 5.49 | 8.51 |
| ROA(%) | 8.96 | 22.14 | 10.15 | 16.03 | 18.19 | 20.21 | 8.61 | 14.11 |
| ROE(%) | 29.77 | 59.59 | 20.1 | 29.78 | 33.03 | 31.53 | 10.6 | 15.47 |
| ROCE(%) | 21.63 | 44.86 | 21.03 | 29.05 | 29.93 | 31.28 | 13.65 | 20.78 |
| Receivable days | 53.02 | 48.06 | 47.07 | 58.59 | 54.96 | 48.94 | 63.49 | 55.64 |
| Inventory Days | 50.52 | 40.77 | 39.65 | 39.48 | 40.77 | 44.69 | 43.6 | 35.96 |
| Payable days | 5.26 | 5.56 | 4.36 | 5.38 | 4.6 | 3.94 | 5.5 | 6.72 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 21.86 | 18.41 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 1.69 | 2.54 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.33 |
| EV/Net Sales(x) | 0.25 | 0.15 | 0.13 | 0.16 | 0.14 | 0.12 | 0.81 | 1.27 |
| EV/Core EBITDA(x) | 2.9 | 1.12 | 1.93 | 1.44 | 1.3 | 1.14 | 10.14 | 11.12 |
| Net Sales Growth(%) | 0 | 35.75 | 17.67 | 8.99 | 40.78 | 28.03 | -14.9 | 27 |
| EBIT Growth(%) | 0 | 121.69 | -42.65 | 82.01 | 38.12 | 27.66 | -42.58 | 93.47 |
| PAT Growth(%) | 0 | 175.12 | -44.69 | 106.4 | 49.75 | 31.69 | -43.46 | 107.92 |
| EPS Growth(%) | 0 | 149.94 | -43.84 | 80.9 | 70.68 | 37.34 | -54.54 | 107.46 |
| Debt/Equity(x) | 2.02 | 0.96 | 0.62 | 0.69 | 0.62 | 0.34 | 0.03 | 0 |
| Current Ratio(x) | 1.57 | 1.98 | 2.23 | 2.07 | 2.2 | 3.34 | 9.98 | 19.91 |
| Quick Ratio(x) | 0.95 | 1.24 | 1.38 | 1.49 | 1.33 | 1.99 | 8.57 | 14.91 |
| Interest Cover(x) | 3.57 | 7.25 | 3.96 | 8.73 | 9.42 | 15.33 | 11.76 | 73.33 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 27% | 11% | 16% | 0% |
| Operating Profit CAGR | 83% | 13% | 29% | 0% |
| PAT CAGR | 109% | 16% | 37% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 14% | NA% | NA% | NA% |
| ROE Average | 15% | 19% | 24% | 29% |
| ROCE Average | 21% | 22% | 25% | 27% |
JG Chemicals Ltd.
Adventz Infinity@5, Unit No. 1511 Street No. 18, B N Block, Sector – V Salt Lake City
JG Chemicals Ltd.
Keynote Financial Services Ltd
Centrum Capital Limited
Emkay Global Financial Services Ltd
JG Chemicals Ltd.
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 161 | 181 | 203 | 212 | 209 | 224 | 218 | 220 | 248 | 286 |
| Other Income | 2 | 3 | 0 | 3 | 3 | 4 | 3 | 4 | 3 | 5 |
| Total Income | 163 | 184 | 203 | 216 | 212 | 228 | 221 | 224 | 252 | 292 |
| Total Expenditure | 147 | 164 | 180 | 191 | 186 | 205 | 198 | 202 | 226 | 265 |
| Operating Profit | 16 | 20 | 23 | 25 | 26 | 23 | 23 | 22 | 26 | 27 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 15 | 18 | 21 | 23 | 24 | 22 | 22 | 20 | 25 | 25 |
| Provision for Tax | 4 | 5 | 5 | 6 | 6 | 6 | 5 | 5 | 6 | 7 |
| Profit After Tax | 11 | 14 | 16 | 17 | 18 | 16 | 16 | 15 | 18 | 19 |
| Adjustments | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Profit After Adjustments | 10 | 13 | 15 | 17 | 17 | 15 | 16 | 14 | 18 | 18 |
| Adjusted Earnings Per Share | 3.2 | 3.3 | 3.9 | 4.2 | 4.3 | 3.9 | 4 | 3.7 | 4.5 | 4.6 |
When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.
For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.
Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.
Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.
Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.